Eli Lilly Gains on Experimental Shot, Gemini Space Station Rises, Oracle Sinks on 3Q Forecast
On this episode of Stock Movers: - Eli Lilly (LLY) gains 2.6% as a late-stage study showed that a next-generation obesity shot helped patients lose almost a quarter of their body weight, potentially making the experimental drug the most potent weight-loss medicine yet. - Gemini Space Station (GEMI) rose 20% after its application for a derivatives exchange was approved by the Commodity Futures Trading Commission in a move that will allow the company to join the fast-growing field of prediction markets. - Oracle (ORCL) sank 13% after the company forecast 3Q cloud sales growth below analyst…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.